Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Cameron

Showing results (441-450 of 481) with videos related to

Pageof 49
Sort By:
The Lancet. Oncology|March 1, 2011
Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trialLuca Gianni, Urania Dafni, Richard D Gelber, et al.
Nutrients|May 27, 2023
Safety, Tolerability, and Pharmacokinetics of β-Cryptoxanthin Supplementation in Healthy Women: A Double-Blind, Randomized, Placebo-Controlled Clinical TrialKaren M L Tan, Jolene Chee, Kezlyn L M Lim, et al.
Nature Medicine|October 8, 2025
Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trialShanu Modi, William Jacot, Hiroji Iwata, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 18, 2021
Updated Standardized Definitions for Efficacy End Points (STEEP) in Adjuvant Breast Cancer Clinical Trials: STEEP Version 2.0Sara M Tolaney, Elizabeth Garrett-Mayer, Julia White, et al.
The Lancet. Gastroenterology & Hepatology|September 4, 2019
Aspirin as an adjuvant treatment for cancer: feasibility results from the Add-Aspirin randomised trialNalinie Joharatnam-Hogan, Fay Cafferty, Richard Hubner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 19, 2023
Pathologic Complete Response and Individual Patient Prognosis After Neoadjuvant Chemotherapy Plus Anti-Human Epidermal Growth Factor Receptor 2 Therapy of Human Epidermal Growth Factor Receptor 2-Positive Early Breast CancerMarion T van Mackelenbergh, Sibylle Loibl, Michael Untch, et al.
Breast (Edinburgh, Scotland)|March 29, 2020
The requirements of a specialist breast centreLaura Biganzoli, Fatima Cardoso, Marc Beishon, et al.
European Journal of Cancer (Oxford, England : 1990)|January 15, 2023
Ten-year survival of neoadjuvant dual HER2 blockade in patients with HER2-positive breast cancerPaolo Nuciforo, John Townend, Martine J Piccart, et al.
JAMA Oncology|December 1, 2022
Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases: Updated Exploratory Analysis of the HER2CLIMB Randomized Clinical TrialNancy U Lin, Rashmi K Murthy, Vandana Abramson, et al.
Lancet (London, England)|July 23, 2013
2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trialAron Goldhirsch, Richard D Gelber, Martine J Piccart-Gebhart, et al.
Pageof 49

Showing results (441-450 of 481) with videos related to

Sort By:
Pageof 49
The Lancet. Oncology|March 1, 2011
Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trialLuca Gianni, Urania Dafni, Richard D Gelber, et al.
Nutrients|May 27, 2023
Safety, Tolerability, and Pharmacokinetics of β-Cryptoxanthin Supplementation in Healthy Women: A Double-Blind, Randomized, Placebo-Controlled Clinical TrialKaren M L Tan, Jolene Chee, Kezlyn L M Lim, et al.
Nature Medicine|October 8, 2025
Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trialShanu Modi, William Jacot, Hiroji Iwata, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 18, 2021
Updated Standardized Definitions for Efficacy End Points (STEEP) in Adjuvant Breast Cancer Clinical Trials: STEEP Version 2.0Sara M Tolaney, Elizabeth Garrett-Mayer, Julia White, et al.
The Lancet. Gastroenterology & Hepatology|September 4, 2019
Aspirin as an adjuvant treatment for cancer: feasibility results from the Add-Aspirin randomised trialNalinie Joharatnam-Hogan, Fay Cafferty, Richard Hubner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 19, 2023
Pathologic Complete Response and Individual Patient Prognosis After Neoadjuvant Chemotherapy Plus Anti-Human Epidermal Growth Factor Receptor 2 Therapy of Human Epidermal Growth Factor Receptor 2-Positive Early Breast CancerMarion T van Mackelenbergh, Sibylle Loibl, Michael Untch, et al.
Breast (Edinburgh, Scotland)|March 29, 2020
The requirements of a specialist breast centreLaura Biganzoli, Fatima Cardoso, Marc Beishon, et al.
European Journal of Cancer (Oxford, England : 1990)|January 15, 2023
Ten-year survival of neoadjuvant dual HER2 blockade in patients with HER2-positive breast cancerPaolo Nuciforo, John Townend, Martine J Piccart, et al.
JAMA Oncology|December 1, 2022
Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases: Updated Exploratory Analysis of the HER2CLIMB Randomized Clinical TrialNancy U Lin, Rashmi K Murthy, Vandana Abramson, et al.
Lancet (London, England)|July 23, 2013
2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trialAron Goldhirsch, Richard D Gelber, Martine J Piccart-Gebhart, et al.
Pageof 49